Navigation Links
High-dose flu vaccines appear to safely boost immunity in elderly

High-dose influenza vaccines may increase elderly patients' immune response without significant adverse effects, offering this vulnerable population additional protection against the flu, according to an article in the May 22 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

Vaccines containing inactivated influenza virus have been available for 50 years to prevent flu and its complications, according to background information in the article. Immune responses decrease with age, however, and currently available flu vaccines are not always effective in the elderly. Recommended vaccines contain 15 micrograms (ìg) of inactivated virus per strain.

Wendy A. Keitel, M.D., Baylor College of Medicine, Houston, and colleagues studied the response to vaccines containing 15, 30 and 60 ìg of virus among 202 individuals age 65 years and older (average age 72.4) in 2002. The 60-ìg level was selected as the highest dosage because manufacturers would reasonably be able to produce that type of vaccine. Participants were randomly assigned to receive one of the three vaccines or a placebo injection and then were monitored daily for one week afterward. They were also examined 30 minutes, two days and 28 days after the vaccine and were contacted six months later to inquire about serious adverse events or side effects. Blood was drawn before the immunization and one month after.

On average, individuals who received higher dosages of vaccine had higher concentrations of antibodies against the flu virus in their blood one month later. In addition, a larger percentage of those who received the higher-dose vaccines had what physicians believe is a sufficient immune response to protect them from developing the flu if they were exposed to the virus. All three vaccine dosage levels were safe and well tolerated, according to the researchers. Although discomfort, redness or swelling at the site of the injection was more common among those who
'"/>

Source:JAMA and Archives Journals


Page: 1 2

Related biology news :

1. High-dose anticlotting drug cuts heart attack, death risk in half
2. Live vaccines more effective against horse herpes virus
3. Designing vaccines by computer
4. Improving the potential of cancer vaccines
5. Report focuses on challenges to unlocking future promise of vaccines
6. Medical experts: US unlikely to have enough vaccines to stop avian flu
7. Plant-derived vaccines safeguard against deadly plague
8. Handling HPV vaccines and screening: The views of 100 authors
9. Protecting virus offers instant flu protection and converts flu infections into their own vaccines
10. Super enzyme may lead way to better tumor vaccines
11. Cellulose nanocrystal research could lead to new vaccines, computer inks
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: High dose flu vaccines appear safely boost immunity elderly

(Date:2/13/2015)... -- ACT Genomics Co., Ltd., a cancer molecular ... genomic information into precision diagnosis and personalized treatments, ... million in the its first private funding round. ... , ACT Genomics has developed comprehensive cancer ... implement next generation sequencing (NGS) and multiplex molecular ...
(Date:2/10/2015)... 10, 2015  Alere Inc. (NYSE: ALR), a ... results for the quarter ended December 31, 2014. ... President of Alere said, "We made substantial progress ... the global leader in rapid diagnostics and delivering ... Health divestiture in early January enabled us to ...
(Date:2/5/2015)... 2015   Epic Sciences , a precision diagnostics company ... Murali Prahalad , Ph.D., president and CEO, is scheduled ... (PMWC) 2015: Silicon Valley, which is taking place at the ... on January 26-28, 2015. Dr. Prahalad ... Biomarkers." Last year, Epic Sciences was a finalist in the ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35
... seeds produced by many tropical trees were probably once ingested ... dispersed the seeds over large distances. But gomphotheres were probably ... aren,t large-seeded plants also extinct? A new Smithsonian report to ... of the National Academy of Sciences during the week ...
... BUFFALO, N.Y. -- While Spider-Man is capturing the imagination ... are working intently to save a young boy,s life. ... a stockbroker from the Buffalo suburbs, discovered that his ... fatal. It strikes only boys, causing their muscles to ...
... rare type of cancer thought to derive from cells in ... one type of liver cell morphs into a totally different ... UCSF researchers triggered this kind of cellular transformationand caused tumors ... suggests that drugs that are able to target those genes ...
Cached Biology News:Have thieving rodents saved tropical trees? 2Deadly liver cancer may be triggered by cells changing identity, UCSF study shows 2Deadly liver cancer may be triggered by cells changing identity, UCSF study shows 3
(Date:3/4/2015)... NEWTOWN, Pa. , March 4, 2015 ... trials services and technology provider, today announced ... and 10 countries convened at its annual ... Spain to discuss the use ... development challenges. BioClinica,s eClinical technologies include: the ...
(Date:3/4/2015)... PARIS , March 4, 2015 ... de Paris in December 2011, ... study of yttrium-90 resin microspheres versus sorafenib in advanced ... results expected late 2016.   SARAH, a ... liver cancer (hepatocellular carcinoma, or HCC) has completed patient ...
(Date:3/3/2015)... March 3, 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: ... and molecular diagnostics that target the underlying mechanisms of ... seventh-month period ended December 31, 2014. Effective ... end from May 31 to December 31. As a ... today are for the quarter and the seven months ...
(Date:3/3/2015)... 03, 2015 Experts and industry insiders ... one event: the Alltech REBELation exploring innovation, inspiration and ... Now in its 31st year, Alltech’s annual international conference ... and the opportunity to join the REBELation at an ... 11:59 p.m. EST, at which point the standard early ...
Breaking Biology Technology:BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4
... in its 3rd edition., WASHINGTON, Aug. ... of Building Biotechnology, the definitive biotechnology industry,primer ... This new,edition adds over 100 pages of ... figures and tables, and many new case ...
... -- Record consolidated revenues of $14.9 million ... -- Record international revenues of $2.3 million - 49% growth ... million -- Secured $10 million credit facility - expands capital resources, -- Reported MIS ... ...
... hits key insulin and Apo AI(Milano), milestones, ... /PRNewswire-FirstCall/ - SemBioSys Genetics Inc.,(TSX:SBS), a biotechnology company ... cardiovascular diseases, today announced its,2008 second quarter financial ... Program, - Submitted an Investigational ...
Cached Biology Technology:New Book on the Business of Biotechnology 2AtriCure Reports Record Second Quarter 2008 Financial Results 2AtriCure Reports Record Second Quarter 2008 Financial Results 3AtriCure Reports Record Second Quarter 2008 Financial Results 4AtriCure Reports Record Second Quarter 2008 Financial Results 5AtriCure Reports Record Second Quarter 2008 Financial Results 6AtriCure Reports Record Second Quarter 2008 Financial Results 7AtriCure Reports Record Second Quarter 2008 Financial Results 8SemBioSys announces second quarter 2008 financial and operational results 2SemBioSys announces second quarter 2008 financial and operational results 3SemBioSys announces second quarter 2008 financial and operational results 4SemBioSys announces second quarter 2008 financial and operational results 5SemBioSys announces second quarter 2008 financial and operational results 6SemBioSys announces second quarter 2008 financial and operational results 7SemBioSys announces second quarter 2008 financial and operational results 8SemBioSys announces second quarter 2008 financial and operational results 9SemBioSys announces second quarter 2008 financial and operational results 10SemBioSys announces second quarter 2008 financial and operational results 11SemBioSys announces second quarter 2008 financial and operational results 12SemBioSys announces second quarter 2008 financial and operational results 13
... The Rotofor purification system with PowerPac 3000 ... protein separation and purification by liquid-phase isoelectric ... mini (18 ml) and standard (60 ml) ... electrode chambers, PowerPac 3000 power supply, 10 ...
... Bio-Rad Molecular Imager VersaDoc MP 4000 ... CCD based imaging system capable of ... methods, including fluorescence, chemiluminescence, densitometry, and ... illumination sources allow imaging of multiplexed ...
...
...
Biology Products: